文献速递泌尿生殖技术与安全MRPET

高危前列腺癌分期中全身PET/MRI各MRI序列的比较

Comparison of MRI Sequences in Whole-Body PET/MRI for Staging of Patients With High-Risk Prostate Cancer.
PubMed 文献 · AJR Am J Roentgenol · 2018-10-17

基于58例未治疗高危前列腺癌患者的前瞻性研究数据,比较全身18F-氟胆碱PET/MRI中Dixon T1加权、Turbo反转恢复幅度、全身DWI和钆增强T1加权VIBE序列对转移灶的检出率和显示清晰度。钆增强T1加权VIBE和全身DWI对转移灶的显示清晰度高于Dixon T1加权序列(分别为p<0.0001和p=0.0011)。结论认为转移灶在DWI或钆增强T1加权VIBE序列上显示最佳,钆增强T1加权VIBE是时间效率最高且病灶检出率和清晰度最高的序列。

要点

  • 钆增强T1加权VIBE病灶检出率97.4%(75/77),全身DWI为95.2%(40/42)。
  • 钆增强T1加权VIBE中92.2%(71/77)病灶获中等或高清晰度评分,全身DWI为90.5%(38/42)。
  • 钆增强T1加权VIBE和全身DWI的转移灶清晰度高于Dixon T1加权(p<0.0001和p=0.0011)。

核心结论

  • 前列腺癌转移灶在DWI或钆增强T1加权VIBE序列上检出最佳,钆增强T1加权VIBE是时间效率最高且病灶检出率和清晰度最高的序列。

研究设计与样本

  • 基于前瞻性研究数据,纳入58例未治疗高危前列腺癌患者,其中10例接受一体化全身18F-氟胆碱PET/MRI、48例接受18F-氟胆碱PET/CT和全身MRI;参考标准为组织病理学或临床和影像随访或两者。

关键影像表现/征象

  • 全身DWI病灶检出率为95.2%(40/42),90.5%(38/42)病灶获中等或高清晰度评分。
  • 钆增强T1加权VIBE病灶检出率为97.4%(75/77),92.2%(71/77)病灶获中等或高清晰度评分。
  • Dixon T1加权病灶检出率为88.3%(68/77),62.3%(48/77)病灶获中等或高清晰度评分。

诊断标准与关键数值

  • 病灶清晰度由两位放射科医生采用4级序数评分(0-3分)定性评估。
  • 钆增强T1加权VIBE和全身DWI的转移灶清晰度高于Dixon T1加权序列,p<0.0001和p=0.0011。

临床应用与阅片要点

  • 全身采集时间:Dixon T1加权1分25秒,Turbo反转恢复幅度15分7秒,全身DWI16分33秒,钆增强T1加权VIBE1分28秒。
  • Turbo反转恢复幅度病灶检出率为94.8%(73/77),88.3%(68/77)病灶获中等或高清晰度评分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The purpose of this study is to investigate the diagnostic value of various MRI sequences used for whole-body (WB) 18F-fluorocholine (FCH) PET/MRI staging of patients with high-risk prostate cancer (PCa).

SUBJECTS AND METHODS: This analysis is based on data from a prospective study that included 58 patients with untreated high-risk PCa who underwent integrated WB FCH PET/MRI (n = 10) or FCH PET/CT and WB MRI (n = 48). Metastatic sites were recorded. The standard of reference was histopathologic findings or clinical and imaging follow-up, or both. For each MRI sequence (Dixon T1-weighted, turbo inversion recovery magnitude, WB DWI, and gadolinium-enhanced T1-weighted volumetric interpolated breath-hold examination [VIBE]), acquisition time was recorded, and conspicuity of metastatic lesions was qualitatively assessed by two radiologists using a 4-point ordinal scale (0-3).

RESULTS: Total WB acquisition times were 1 minute 25 seconds for Dixon T1-weighted, 15 minutes 7 seconds for turbo inversion recovery magnitude, 16 minutes 33 seconds for WB DWI, and 1 minute 28 seconds for gadolinium-enhanced T1-weighted VIBE. The lesion detection rates were 88.3% (68/77) for Dixon T1-weighted, 94.8% (73/77) for turbo inversion recovery magnitude, 95.2% (40/42) for WB DWI, and 97.4% (75/77) for gadolinium-enhanced T1-weighted VIBE sequences. Moderate or high conspicuity scores were assigned to 62.3% (48/77) of lesions for Dixon T1-weighted, 88.3% (68/77) of lesions for turbo inversion recovery magnitude, 90.5% (38/42) of lesions for WB DWI, and 92.2% (71/77) of lesions for gadolinium-enhanced T1-weighted VIBE sequences. Conspicuity of metastases on gadolinium-enhanced T1-weighted VIBE and WB DWI sequences was higher than that on Dixon T1-weighted sequences (p < 0.0001 and p = 0.0011, respectively).

CONCLUSION: Metastases from prostate cancer are best detected at DWI or gadolinium-enhanced T1-weighted VIBE sequences. The most time-efficient sequence with the highest lesion detection rate and conspicuity is gadolinium-enhanced T1-weighted VIBE.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Metser U, Chan R, Veit-Haibach P, et al. Comparison of MRI Sequences in Whole-Body PET/MRI for Staging of Patients With High-Risk Prostate Cancer. AJR Am J Roentgenol. 2018. PMID: 30332285. doi:10.2214/AJR.18.20495

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。